Pacific Biosciences Of California reported $428.57M in Cash and Equivalent for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Accelerate Diagnostics AXDX:US 13.65M 26.24M
Agilent A:US $ 1186M 73M
Bruker BRKR:US $ 816.1M 252.1M
Danaher DHR:US $ 3717M 1131M
Fluidigm FLDM:US $ 29.98M 1.53M
General Electric GE:US $ 12842M 2928M
Illumina ILMN:US $ 1351M 119M
Myriad Genetics MYGN:US $ 27.2M 231.2M
Nanostring Technologies NSTG:US $ 98.46M 8.61M
Pacific Biosciences Of California PACB:US $ 428.57M 32.15M
Perkinelmer PKI:US $ 669.76M 51.44M
Quidel QDEL:US $ 1275.54M 472.78M
Thermo Fisher Scientific TMO:US $ 2752M 1725M
Waters WAT:US $ 480.07M 21.16M